These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10636451)

  • 21. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
    Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
    Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retrospective study of the cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in Guthrie cards from a large cohort of neonatal screening for cystic fibrosis.
    Verlingue C; Mercier B; Lecoq I; Audrézet MP; Laroche D; Travert G; Férec C
    Hum Genet; 1994 Apr; 93(4):429-34. PubMed ID: 7513292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
    Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
    Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
    Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
    Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
    [No Abstract]   [Full Text] [Related]  

  • 25. False negatives in the newborn screening for cystic fibrosis in Western Andalusia: Results from a 10-year experience.
    Escudero-Ávila R; Delgado-Pecellín C; Moreno-Valera MJ; Carrasco-Hernández L; Quintana-Gallego ME; Delgado-Pecellín I
    Pediatr Pulmonol; 2023 Sep; 58(9):2464-2468. PubMed ID: 36196044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis.
    Padoan R; Genoni S; Moretti E; Seia M; Giunta A; Corbetta C
    Acta Paediatr; 2002; 91(1):82-7. PubMed ID: 11883825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis.
    Scotet V; De Braekeleer M; Audrézet MP; Lodé L; Verlingue C; Quéré I; Mercier B; Duguépéroux I; Codet JP; Moineau MP; Parent P; Férec C
    Clin Genet; 2001 Jan; 59(1):42-7. PubMed ID: 11168024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Demographics of the UK cystic fibrosis population: implications for neonatal screening.
    McCormick J; Green MW; Mehta G; Culross F; Mehta A
    Eur J Hum Genet; 2002 Oct; 10(10):583-90. PubMed ID: 12357328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.
    Lecoq I; Brouard J; Laroche D; Férec C; Travert G
    Acta Paediatr; 1999 Mar; 88(3):338-41. PubMed ID: 10229049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newborn Screening for Cystic Fibrosis in California.
    Kharrazi M; Yang J; Bishop T; Lessing S; Young S; Graham S; Pearl M; Chow H; Ho T; Currier R; Gaffney L; Feuchtbaum L;
    Pediatrics; 2015 Dec; 136(6):1062-72. PubMed ID: 26574590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CFTR mutations and IVS8-5T variant in newborns with hypertrypsinaemia and normal sweat test.
    Castellani C; Bonizzato A; Mastella G
    J Med Genet; 1997 Apr; 34(4):297-301. PubMed ID: 9138152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic sequencing in cystic fibrosis newborn screening: what works best, two-tier predefined CFTR mutation panels or second-tier CFTR panel followed by third-tier sequencing?
    Currier RJ; Sciortino S; Liu R; Bishop T; Alikhani Koupaei R; Feuchtbaum L
    Genet Med; 2017 Oct; 19(10):1159-1163. PubMed ID: 28471435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy.
    Audrézet MP; Munck A; Scotet V; Claustres M; Roussey M; Delmas D; Férec C; Desgeorges M
    Genet Med; 2015 Feb; 17(2):108-16. PubMed ID: 25122143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
    Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
    Padoan R; Bassotti A; Seia M; Corbetta C
    Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.
    Bobadilla JL; Macek M; Fine JP; Farrell PM
    Hum Mutat; 2002 Jun; 19(6):575-606. PubMed ID: 12007216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of the French cystic fibrosis newborn screening programme by a centralized tracking process.
    Munck A; Delmas D; Audrézet MP; Lemonnier L; Cheillan D; Roussey M
    J Med Screen; 2018 Mar; 25(1):6-12. PubMed ID: 28454512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.